SCHEMBL4767295

SCHEMBL4767295

Clc1ccc2c(C3CCNCC3)cn(CCN3CCOCC3)c2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 2/20 0.47
HTR6 P50406 2/20 0.47
KCNH2 Q12809 5/20 0.43
CNR1 P21554 2/20 0.41
MLNR O43193 1/20 0.41
CACNA1F O60840 1/20 0.41
NR1I2 O75469 1/20 0.41
ABCB11 O95342 1/20 0.41
ABCB1 P08183 1/20 0.41
ADRB1 P08588 1/20 0.41
ADRA2A P08913 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
CHRM1 P11229 1/20 0.41
DRD2 P14416 1/20 0.41
ADRA2B P18089 1/20 0.41
ADRA2C P18825 1/20 0.41
CHRM3 P20309 1/20 0.41
MAOA P21397 1/20 0.41
DRD1 P21728 1/20 0.41
DRD4 P21917 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5342259 0.84 CNR2 (0.53) HTR6CNR1CNR2
SCHEMBL4773949 0.78 SCN9A (0.49) CNR1SCN9AMAPTCNR2
SCHEMBL4882103 0.77 HTR6 (0.50) HTR1AHTR6KCNH2CNR1SLC6A2
SCHEMBL22773345 0.76 APP (0.62) HTR1AHTR6KCNH2DRD2SLC6A2
SCHEMBL29734609 0.76 APP (0.62) HTR1AHTR6KCNH2DRD2SLC6A2
SCHEMBL21381836 0.73 KCNH2 (0.56) HTR1AHTR6KCNH2CNR1MLNR
SCHEMBL29511847 0.73 KCNH2 (0.56) HTR1AHTR6KCNH2CNR1MLNR
SCHEMBL22491590 0.72 HTR6 (0.55) HTR1AHTR6KCNH2SLC6A2SLC6A4
SCHEMBL23211798 0.70 KCNH2 (0.53) HTR1AHTR6KCNH2CNR1MLNR
SCHEMBL21385840 0.69 KCNH2 (0.57) HTR1AHTR6KCNH2CNR1MLNR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1315492-B1 USE OF SUBSTITUTED PYRAZOLES FOR THE TREATMENT OF ALLERGIES ORTHO MCNEIL PHARM INC (US) 2008-07-30 EP disclosed
US-7265102-B2 Substituted pyrazoles ORTHO MCNEIL PHARMACEUTICAL, INC. (US) 2007-09-04 US disclosed
EP-1309592-B9 SUBSTITUTED PYRAZOLES ORTHO MCNEIL PHARM INC (US) 2007-02-28 EP disclosed
EP-1309592-B1 SUBSTITUTED PYRAZOLES ORTHO MCNEIL PHARM INC (US) 2006-04-26 EP disclosed
US-20050234102-A1 Substituted pyrazoles CAI HUI 2005-10-20 US disclosed
US-6951851-B2 Substituted pyrazoles CAI HUI 2005-10-04 US disclosed
US-6949540-B2 Substituted pyrazoles ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2005-09-27 US disclosed
US-6936603-B2 Substituted pyrazoles ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2005-08-30 US disclosed
US-20040044027-A1 Substituted pyrazoles CAI HUI (US) 2004-03-04 US disclosed
US-20030229075-A1 Substituted pyrazoles CAI HUI (US) 2003-12-11 US disclosed
US-20030225063-A1 Substituted pyrazoles ORTHO MCNEIL PHARMACEUTICAL, INC. 2003-12-04 US disclosed
US-20030225062-A1 Substituted pyrazoles ORTHO MCNEIL PHARMACEUTICAL, INC. 2003-12-04 US disclosed
US-6635633-B2 Substituted pyrazoles ORTHO-PHARMACEUTICAL, INC. 2003-10-21 US disclosed
US-6579896-B2 Immunology response; autoimmune disease ORTHO-MCNEIL PHARMACEUTICAL, INC. 2003-06-17 US disclosed
US-20020147189-A1 Method for treating allergies using substituted pyrazoles ORTHO MCNEIL PHARMACEUTICAL, INC. 2002-10-10 US disclosed
US-20020040019-A1 Substituted pyrazoles ORTHO MCNEIL PHARMACEUTICAL, INC. 2002-04-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225062-A1 Substituted pyrazoles CTSS, CTSZ, CTSV HTR1A 4279/4885HTR6 4705/4885KCNH2 3779/4885
US-20030229075-A1 Substituted pyrazoles CTSS, CTSZ, CTSV HTR1A 4279/4885HTR6 4705/4885KCNH2 3779/4885
US-20020040019-A1 Substituted pyrazoles CTSS, CTSZ, CTSV HTR1A 4279/4885HTR6 4705/4885KCNH2 3779/4885
US-20040044027-A1 Substituted pyrazoles CTSS, CTSZ, CTSV HTR1A 4279/4885HTR6 4705/4885KCNH2 3779/4885
US-20030225063-A1 Substituted pyrazoles CTSS, CTSZ, CTSV HTR1A 4279/4885HTR6 4705/4885KCNH2 3779/4885
US-20020147189-A1 Method for treating allergies using substituted pyrazoles TSLP, IL33, HRH2 HTR1A 1554/4885HTR6 1434/4885KCNH2 1858/4885
US-20050234102-A1 Substituted pyrazoles CTSS, CTSZ, CTSV HTR1A 4279/4885HTR6 4705/4885KCNH2 3779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.